drugset / Trial / NCT02059499
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Phase 3
Completed
91 enrolled
AIDS Malignancy Consortium
National Cancer Institute (NCI) · collabThe Emmes Company, LLC · collabUniversity of Arkansas · collab
RandomizedCrossoverSingle-blindTreatment
Summary
This randomized phase III trial studies imiquimod or fluorouracil to see how well they work compared to observation in treating patients with high-grade anal squamous skin lesions who are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether imiquimod or fluorouracil is more effective than observation in treating high-grade anal squamous skin lesions.
Timeline
- Start
- 2015-12-28
- Primary completion
- 2023-12-05
- Completion
- 2024-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imiquimod | Other / unclassified | 2.5 % | Other |
| Subject | fluorouracil | Small molecule | 5 % | Other |